- Home
- MFA vs ABUS Comparison
MFA vs ABUS Comparison
Compare MFA & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- ABUS
- Stock Information
- Founded
- MFA 1997
- ABUS 2005
- Country
- MFA United States
- ABUS United States
- Employees
- MFA N/A
- ABUS N/A
- Industry
- MFA Real Estate Investment Trusts
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- ABUS Health Care
- Exchange
- MFA Nasdaq
- ABUS Nasdaq
- Market Cap
- MFA 930.2M
- ABUS 828.9M
- IPO Year
- MFA N/A
- ABUS N/A
- Fundamental
- Price
- MFA $9.69
- ABUS $4.39
- Analyst Decision
- MFA Buy
- ABUS Strong Buy
- Analyst Count
- MFA 7
- ABUS 2
- Target Price
- MFA $10.96
- ABUS $5.00
- AVG Volume (30 Days)
- MFA 1.3M
- ABUS 1.1M
- Earning Date
- MFA 11-06-2025
- ABUS 11-13-2025
- Dividend Yield
- MFA 14.95%
- ABUS N/A
- EPS Growth
- MFA N/A
- ABUS N/A
- EPS
- MFA 0.86
- ABUS N/A
- Revenue
- MFA $279,011,000.00
- ABUS $14,606,000.00
- Revenue This Year
- MFA N/A
- ABUS $138.02
- Revenue Next Year
- MFA $14.85
- ABUS N/A
- P/E Ratio
- MFA $11.20
- ABUS N/A
- Revenue Growth
- MFA N/A
- ABUS 116.64
- 52 Week Low
- MFA $7.85
- ABUS $2.71
- 52 Week High
- MFA $11.28
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- MFA 64.52
- ABUS 48.80
- Support Level
- MFA $8.94
- ABUS $4.08
- Resistance Level
- MFA $9.18
- ABUS $4.42
- Average True Range (ATR)
- MFA 0.18
- ABUS 0.22
- MACD
- MFA 0.05
- ABUS -0.03
- Stochastic Oscillator
- MFA 98.71
- ABUS 41.14
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.